Drug intelligence / Profile preview

efineptakin alpha

Development stage: Unknown
Lead developer: NeoImmuneTech
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

Efineptakin alpha, also known as TJ107 or GX-I7, and marketed as HyLeukin, is a long-acting recombinant human interleukin-7 (rhIL-7) developed using Genexine's proprietary hyFc® platform. It is designed to boost T lymphocytes and restore immune function, primarily addressing conditions like lymphopenia, a common and severe side effect of standard cancer treatments. The drug is being developed by Genexine, I-Mab, and TJ Biopharma Co., Ltd. for various solid tumors and glioblastoma multiforme.

Brand names: HyLeukin

Targets

IL7R (Interleukin-7 Receptor)

Beyond the preview

Go deeper on efineptakin alpha.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on efineptakin alpha.

Explore the full profile